Antibody–Drug Conjugates for Bladder Sparing: Lessons from Sure-02 Trial
27 Feb 20264 min read0 viewsJournal Feed
GIST (Key Takeaways)
Historically, perioperative cisplatin based neoadjuvant therapy has remained the gold standard for muscle-invasive bladder cancer.
In the past 5 years, several practice changing trials have enabled the incorporation of immune checkpoint inhibitors in the perioperative setting for muscle-invasive bladder cancer.
The phase 3 NIAGARA study led to the approval of durvalumab in combination with gemcitabine or cisplatin followed by adjuvant immune checkpoint inhibitor monotherapy.1 The CheckMate-274 and AMBASSADOR trials showed improved outcomes in patients treated with adjuvant immune checkpoint inhibitors.
Clinical Editorial
The Lancet Oncology published a clinical update in Oncology on 27 Feb 2026.
The item focuses on Antibody–drug conjugates for bladder sparing: lessons from SURE-02 trial.
Review the original article for the full source wording and details.
Source Reference
Read the full original publication from the source journal or publisher link below.